Sandy Draper
Stock Analyst at Guggenheim
(2.92)
# 1,556
Out of 4,876 analysts
119
Total ratings
58.33%
Success rate
19.78%
Average return
Main Sectors:
Stocks Rated by Sandy Draper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MEDP Medpace Holdings | Maintains: Buy | $464 → $432 | $310.69 | +39.05% | 12 | Jul 24, 2024 | |
| IQV IQVIA Holdings | Downgrades: Neutral | n/a | $157.47 | - | 8 | Feb 15, 2024 | |
| CRL Charles River Laboratories International | Downgrades: Neutral | n/a | $150.01 | - | 15 | Feb 15, 2024 | |
| EVH Evolent Health | Maintains: Hold | $36 → $34 | $11.16 | +204.66% | 9 | Nov 14, 2023 | |
| GDRX GoodRx Holdings | Maintains: Buy | $8 → $10 | $4.90 | +104.08% | 4 | Aug 10, 2023 | |
| DOCS Doximity | Downgrades: Neutral | n/a | $61.09 | - | 3 | Aug 9, 2023 | |
| TOI The Oncology Institute | Maintains: Buy | $3 → $2 | $2.19 | -8.68% | 3 | Jun 16, 2023 | |
| ICLR ICON Public Limited Company | Maintains: Buy | $271 → $263 | $144.56 | +81.93% | 13 | Apr 28, 2023 | |
| AGL agilon health | Maintains: Buy | $21 → $30 | $2.31 | +1,198.70% | 3 | Mar 6, 2023 | |
| HQY HealthEquity | Maintains: Buy | $89 → $94 | $104.88 | -10.37% | 11 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $8.41 | - | 10 | Oct 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $51 | $22.00 | +131.82% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $143 → $129 | $167.96 | -23.20% | 2 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $55 | $27.38 | +100.88% | 2 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $226 → $168 | $53.65 | +213.14% | 2 | May 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $12 | $49.41 | -75.71% | 1 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $33 → $38 | $21.61 | +75.84% | 7 | Feb 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $6.58 | +659.88% | 1 | Jan 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $65 | $7.17 | +806.56% | 1 | Jan 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $36 | $3.81 | +844.88% | 4 | May 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $167 | $283.41 | -41.07% | 3 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $1.49 | - | 2 | May 31, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $63 | $18.34 | +243.51% | 1 | Sep 20, 2016 |
Medpace Holdings
Jul 24, 2024
Maintains: Buy
Price Target: $464 → $432
Current: $310.69
Upside: +39.05%
IQVIA Holdings
Feb 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $157.47
Upside: -
Charles River Laboratories International
Feb 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $150.01
Upside: -
Evolent Health
Nov 14, 2023
Maintains: Hold
Price Target: $36 → $34
Current: $11.16
Upside: +204.66%
GoodRx Holdings
Aug 10, 2023
Maintains: Buy
Price Target: $8 → $10
Current: $4.90
Upside: +104.08%
Doximity
Aug 9, 2023
Downgrades: Neutral
Price Target: n/a
Current: $61.09
Upside: -
The Oncology Institute
Jun 16, 2023
Maintains: Buy
Price Target: $3 → $2
Current: $2.19
Upside: -8.68%
ICON Public Limited Company
Apr 28, 2023
Maintains: Buy
Price Target: $271 → $263
Current: $144.56
Upside: +81.93%
agilon health
Mar 6, 2023
Maintains: Buy
Price Target: $21 → $30
Current: $2.31
Upside: +1,198.70%
HealthEquity
Dec 7, 2022
Maintains: Buy
Price Target: $89 → $94
Current: $104.88
Upside: -10.37%
Oct 24, 2022
Upgrades: Neutral
Price Target: n/a
Current: $8.41
Upside: -
Aug 12, 2022
Maintains: Buy
Price Target: $36 → $51
Current: $22.00
Upside: +131.82%
May 25, 2021
Maintains: Buy
Price Target: $143 → $129
Current: $167.96
Upside: -23.20%
May 18, 2021
Maintains: Buy
Price Target: $84 → $55
Current: $27.38
Upside: +100.88%
May 12, 2021
Maintains: Buy
Price Target: $226 → $168
Current: $53.65
Upside: +213.14%
Apr 21, 2021
Initiates: Hold
Price Target: $12
Current: $49.41
Upside: -75.71%
Feb 4, 2021
Maintains: Hold
Price Target: $33 → $38
Current: $21.61
Upside: +75.84%
Jan 28, 2021
Initiates: Buy
Price Target: $50
Current: $6.58
Upside: +659.88%
Jan 28, 2021
Initiates: Buy
Price Target: $65
Current: $7.17
Upside: +806.56%
May 13, 2020
Maintains: Buy
Price Target: $30 → $36
Current: $3.81
Upside: +844.88%
Mar 26, 2020
Maintains: Buy
Price Target: $175 → $167
Current: $283.41
Upside: -41.07%
May 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $1.49
Upside: -
Sep 20, 2016
Initiates: Buy
Price Target: $63
Current: $18.34
Upside: +243.51%